These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 3881919)
41. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity. Millard RW; Grupp G; Grupp IL; DiSalvo J; DePover A; Schwartz A Circ Res; 1983 Feb; 52(2 Pt 2):I29-39. PubMed ID: 6831652 [TBL] [Abstract][Full Text] [Related]
42. Clinical use of calcium channel blockers as ventricular unloading agents. Guazzi MD; Cipolla C; Sganzerla P; Agostoni PG; Fabbiocchi F; Pepi M Eur Heart J; 1983 Jan; 4 Suppl A():181-7. PubMed ID: 6220895 [TBL] [Abstract][Full Text] [Related]
43. Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects. Zwadlo C; Borlak J Vascul Pharmacol; 2016 Dec; 87():121-128. PubMed ID: 27613148 [TBL] [Abstract][Full Text] [Related]
44. [Are all calcium antagonists alike?]. Bertel O Schweiz Rundsch Med Prax; 1992 Feb; 81(7):164-7. PubMed ID: 1535950 [TBL] [Abstract][Full Text] [Related]
45. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Henry PD Am J Cardiol; 1980 Dec; 46(6):1047-58. PubMed ID: 6255787 [TBL] [Abstract][Full Text] [Related]
46. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Stone PH; Antman EM; Muller JE; Braunwald E Ann Intern Med; 1980 Dec; 93(6):886-904. PubMed ID: 7004293 [TBL] [Abstract][Full Text] [Related]
47. Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials. Opie LH Cardiovasc Drugs Ther; 1988 Jan; 1(5):461-91. PubMed ID: 3154677 [TBL] [Abstract][Full Text] [Related]
48. [The prolonged use of calcium antagonists in myocardial infarct in rats: their effect on hemodynamics and the contractile function and morphology of the heart muscle]. Kazanova GV; Tsorin IB; Chichkanov GG; Zakharov SP; Shchegolev AI; Iavorskiĭ AN; Liubimov BI Eksp Klin Farmakol; 1992; 55(3):17-20. PubMed ID: 1458153 [TBL] [Abstract][Full Text] [Related]
49. Rapid large artery remodeling following the administration and withdrawal of calcium channel blockers in spontaneously hypertensive rats. Vaja V; Ochodnicky P; Krenek P; Klimas J; Bajuszova Z; Kyselovic J Eur J Pharmacol; 2009 Oct; 619(1-3):85-91. PubMed ID: 19683522 [TBL] [Abstract][Full Text] [Related]
50. Differential therapy with calcium antagonists in pulmonary hypertension secondary to COPD. Hemodynamic effects of nifedipine, diltiazem, and verapamil. Gassner A; Sommer G; Fridrich L; Magometschnigg D; Priol A Chest; 1990 Oct; 98(4):829-34. PubMed ID: 2209138 [TBL] [Abstract][Full Text] [Related]
51. Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardial tissue. Schwinger RH; Böhm M; Erdmann E J Cardiovasc Pharmacol; 1990 Jun; 15(6):892-9. PubMed ID: 1694911 [TBL] [Abstract][Full Text] [Related]
55. Sympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipine. Verma SP; Silke B; Hussain M; Nelson GI; Wilson JA; Reynolds GW; Richmond A; Taylor SH J Hypertens; 1988 Nov; 6(11):897-904. PubMed ID: 2906956 [TBL] [Abstract][Full Text] [Related]
56. Hypertension: calcium-blocking agents in treatment. Ambrose JE J Am Osteopath Assoc; 1984 Jan; 83(5):353-60. PubMed ID: 6321407 [No Abstract] [Full Text] [Related]
58. Comparison of the cardiovascular effects of trans-diclofurime with different types of calcium antagonists in conscious spontaneously hypertensive rats. Petty MA; Mir AK Br J Pharmacol; 1988 Aug; 94(4):1218-24. PubMed ID: 3207982 [TBL] [Abstract][Full Text] [Related]
59. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Ishikawa K; Nakai S; Takenaka T; Kanamasa K; Hama J; Ogawa I; Yamamoto T; Oyaizu M; Kimura A; Yamamoto K; Yabushita H; Katori R Circulation; 1997 May; 95(10):2368-73. PubMed ID: 9170398 [TBL] [Abstract][Full Text] [Related]